The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
ApexOnco Front Page
Recent articles
Solstice Oncology acquires porustobart from Harbour Biomed.
CuraDev and OncoNano move into phase 1, trying to avoid the negative precedent of other Sting agonist projects.
Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.
Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.
The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.
A royalty financing deal should see this gene therapy launched nine months after its surprise US approval.